Clinical Trial Evaluating an Amnion Membrane Allograft for Use in the Management of Non- Healing Diabetic Foot Ulcers Versus Standard Of Care

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSkye Biologics Holdings, LLC

About this trial

The main purpose of this research study is to compare the proportion of wound closure in subjects that receive E-GRAFT™ with Standard of Care (SOC) versus FIBRACOL™ with SOC. Other research purposes include the following:

* Rate of wound closure * Change in ulcer size over 12 weeks * Any adverse events or reactions (side effects) * Changes in neuropathy (nerve damage) * Change in pain levels * Occurrence of infection

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Subjects must be at least 18 years of age or older.

Subjects must have a diagnosis of type 1 or 2 Diabetes mellitus.

At randomization subjects must have a target diabetic foot ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 10.0 cm2 measured post debridement with manual measurement.

The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit.

Disqualifiers

Target ulcers located on the plantar aspect of the foot must be offloaded for at least 14 days prior to randomization.

The subject must consent to using the prescribed off-loading method for the duration of the study.

The subject must agree to attend the weekly study visits required by the protocol.

The subject must be willing and able to participate in the informed consent process.

Trial design

Design model

Parallel

Treatments tested in this trial

  • E-GRAFT ™

    Other intervention

    E-GRAFT™ that is a dehydrated thick amniotic allograft processed and approved for use as a Human Cellular and Tissue-Based Product (HCT/P) under FDA 21 CFR 1271 and Section 361 of the Public Health Service (PHS) Act.

  • FIBRACOL™

    Device

    510K FDA cleared Collagen alginate dressing

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: SOC primary dressing with E-GRAFT ™Experimental treatment 1 intervention
Group B: SOC primary dressing with FIBRACOL™Active comparator 1 intervention

Trial outcomes

Primary outcomes

1

Comparison of the proportion of index ulcers "healed" at 12-weeks

Investigator assessment of healing (100% epithelization w/no drainage), measurements of ulcer size using manual measurements

Time frame
12-weeks

Secondary outcomes

1

Time to healing within 12-weeks

Time to healing will be taken as the time of first assessment (i.e. before confirmation within two weeks) of complete healing.

Time frame
12-weeks
2

Percentage Area Reduction over12 week period

Digital imaging

Time frame
12-weeks
3

Changes in peripheral neuropathy

Semmes Weinstein with vibratory, scores

Time frame
12-weeks
4

Change in pain levels during trial

NPRS (Subject Pain Scale), 0-10: The number 0 represents "no pain," the number 5 represents "moderate pain", and the number 10 represents the "worst possible pain."

Time frame
12-weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.